株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ループス腎炎 :パイプライン分析

Lupus Nephritis - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 192685
出版日 ページ情報 英文 142 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
ループス腎炎 :パイプライン分析 Lupus Nephritis - Pipeline Review, H2 2016
出版日: 2016年09月28日 ページ情報: 英文 142 Pages
概要

ループス腎炎とは、全身性エリテマトーデス(SLE:自己免疫疾患の一種)により引き起こされる腎臓の炎症です。主な症状として、体重減少や高血圧、尿が褐色になったり泡立ったりする、などが挙げられます。

当レポートでは、世界各国でのループス腎炎治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

ループス腎炎の概要

治療薬の開発

  • ループス腎炎向けパイプライン製品:概要
  • ループス腎炎向けパイプライン製品:比較分析

各企業で開発中のループス腎炎治療薬

大学/研究機関で研究中のループス腎炎治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

ループス腎炎治療薬:開発中の製品の一覧(企業別)

ループス腎炎治療薬:研究中の製品の一覧(大学/研究機関別)

ループス腎炎治療薬の開発に従事している企業

  • AbbVie Inc.
  • 旭化成ファーマ
  • Azano Pharmaceuticals Inc.
  • Biogen, Inc.
  • Bristol-Myers Squibb Company
  • Deltanoid Pharmaceuticals Inc.
  • F. Hoffmann-La Roche Ltd.
  • FibroStatin SL
  • GlaxoSmithKline Plc
  • HanAll Biopharma Co., Ltd.
  • Invion Limited
  • Millennium Pharmaceuticals, Inc.
  • Ocata Therapeutics, Inc.
  • Zyrnat Biotherapeutics SL

ループス腎炎:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • アバタセプト
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • ベリムマブ
  • BIIB-023
  • BMS-986147
  • DP-001
  • ループス腎炎向けブラジキニン受容体B1拮抗薬
  • FSMAB-26
  • HL-161
  • INV-103
  • ixazomib citrate
  • ミゾリビン
  • ループス腎炎向けモノクローナル抗体
  • オビヌツズマブ
  • P-Dex
  • RO-5461111
  • 自己免疫疾患向け幹細胞療
  • ベネトクラックス
  • ボクロスポリン
  • Y-175L
  • ZY-11

ループス腎炎治療薬:パイプライン製品の最新動向

ループス腎炎治療薬:開発が休止状態の製品

ループス腎炎治療薬:開発が中止された製品

ループス腎炎関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8490IDB

Summary

Global Markets Direct's, 'Lupus Nephritis - Pipeline Review, H2 2016', provides an overview of the Lupus Nephritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Lupus Nephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lupus Nephritis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Lupus Nephritis
  • The report reviews pipeline therapeutics for Lupus Nephritis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Lupus Nephritis therapeutics and enlists all their major and minor projects
  • The report assesses Lupus Nephritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Lupus Nephritis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Lupus Nephritis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Lupus Nephritis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Lupus Nephritis Overview
  • Therapeutics Development
    • Pipeline Products for Lupus Nephritis - Overview
    • Pipeline Products for Lupus Nephritis - Comparative Analysis
  • Lupus Nephritis - Therapeutics under Development by Companies
  • Lupus Nephritis - Therapeutics under Investigation by Universities/Institutes
  • Lupus Nephritis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Lupus Nephritis - Products under Development by Companies
  • Lupus Nephritis - Products under Investigation by Universities/Institutes
  • Lupus Nephritis - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Asahi Kasei Pharma Corp.
    • Astellas Pharma Inc.
    • Aurinia Pharmaceuticals Inc
    • Azano Pharmaceuticals Inc.
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Deltanoid Pharmaceuticals Inc.
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline Plc
    • HanAll Biopharma Co., Ltd.
    • Invion Limited
    • KPI Therapeutics, Inc.
    • MedImmune, LLC
    • Omeros Corporation
    • Ra Pharmaceuticals, Inc.
    • Resolve Therapeutics, LLC
    • Takeda Pharmaceutical Company Limited
    • TxCell SA
  • Lupus Nephritis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • abatacept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • anifrolumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • belimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BI-655064 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-986147 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dalazatide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DP-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Antagonize Bradykinin Receptor B1 for Lupus Nephritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ENTX-DN - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HL-161 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INV-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ixazomib citrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mizoribine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody for Lupus Nephritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • obinutuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMS-721 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • P-Dex - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RA-101495 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RO-5461111 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RSLV-145 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Autoimmune Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Inhibit Complement C5 for Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome and Autoimmune Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • venetoclax - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • voclosporin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Y-175L - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Lupus Nephritis - Dormant Projects
  • Lupus Nephritis - Discontinued Products
  • Lupus Nephritis - Product Development Milestones
    • Featured News & Press Releases
      • Aug 15, 2016: Aurinia Pharmaceuticals Announces Voclosporin Meets Primary Endpoint in Phase IIB AURA-LV Study in Lupus Nephritis
      • Jun 28, 2016: Aurinia Announces 24 Week Remission Rates from the First Seven Patients in its Open Label AURION Study in Lupus Nephritis (LN)
      • Jun 10, 2016: Alliance for Children Therapeutics Presents Dalazatide Data Demonstrating Positive Response in Lupus
      • May 23, 2016: KPI Therapeutics to Present Updated Dalazatide Study Data in Lupus
      • May 12, 2016: Aurinia Announces Presentations at the European Renal Association - European Dialysis and Transplant Association Meeting
      • May 09, 2016: Aurinia Initiates First Clinical Study of Voclosporin for Japan
      • Apr 20, 2016: Patient Dosing Initiated for OMS721 Phase 2 Program in Renal Diseases
      • Mar 29, 2016: Aurinia Announces Result from Data and Safety Monitoring Board for Its Phase 2b Study in Lupus Nephritis - Study to Continue as Planned
      • Mar 02, 2016: Aurina Receives FDA Fast Track Designation for Voclosporin for the Treatment of Lupus Nephritis
      • Feb 08, 2016: Aurinia Announces Preliminary Topline Data From its Open Label Aurion Study in Lupus Nephritis
      • Feb 02, 2016: Deltanoid Pharmaceuticals Announces Appointment of Douglas Jermasek as Chief Executive Officer
      • Jan 19, 2016: Aurinia Announces Completion of Patient Enrollment in Its Phase 2B AURA-LV Study in Lupus Nephritis
      • Dec 03, 2015: Ocata's Hemangio-derived Mesenchymal Cells Preserve Kidney Function and Extend Lifespan in Preclinical Model of Lupus Nephritis
      • Nov 24, 2015: Aurinia Pharmaceuticals Announces Outcome from Data and Safety Monitoring Board for Its Phase 2b Study in Lupus Nephritis - Study to Continue as Planned
      • Nov 10, 2015: Kineta, Seattle Children's Research Institute Present New Data Demonstrating Positive, Predictive Responses to Dalazatide In Lupus
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Lupus Nephritis, H2 2016
  • Number of Products under Development for Lupus Nephritis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Lupus Nephritis - Pipeline by AbbVie Inc, H2 2016
  • Lupus Nephritis - Pipeline by Asahi Kasei Pharma Corp., H2 2016
  • Lupus Nephritis - Pipeline by Astellas Pharma Inc., H2 2016
  • Lupus Nephritis - Pipeline by Aurinia Pharmaceuticals Inc, H2 2016
  • Lupus Nephritis - Pipeline by Azano Pharmaceuticals Inc., H2 2016
  • Lupus Nephritis - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Lupus Nephritis - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Lupus Nephritis - Pipeline by Deltanoid Pharmaceuticals Inc., H2 2016
  • Lupus Nephritis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Lupus Nephritis - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Lupus Nephritis - Pipeline by HanAll Biopharma Co., Ltd., H2 2016
  • Lupus Nephritis - Pipeline by Invion Limited, H2 2016
  • Lupus Nephritis - Pipeline by KPI Therapeutics, Inc., H2 2016
  • Lupus Nephritis - Pipeline by MedImmune, LLC, H2 2016
  • Lupus Nephritis - Pipeline by Omeros Corporation, H2 2016
  • Lupus Nephritis - Pipeline by Ra Pharmaceuticals, Inc., H2 2016
  • Lupus Nephritis - Pipeline by Resolve Therapeutics, LLC, H2 2016
  • Lupus Nephritis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Lupus Nephritis - Pipeline by TxCell SA, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Lupus Nephritis - Dormant Projects, H2 2016
  • Lupus Nephritis - Dormant Projects (Contd..1), H2 2016
  • Lupus Nephritis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Lupus Nephritis, H2 2016
  • Number of Products under Development for Lupus Nephritis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top